- A scDb-based trivalent bispecific antibody for T-cell-mediated killing of HER3-expressing cancer cells
Nadine Aschmoneit et al, 2021, Scientific Reports CrossRef - Fc-comprising scDb-based trivalent, bispecific T-cell engagers for selective killing of HER3-expressing cancer cells independent of cytokine release
Nadine Aschmoneit et al, 2021, Journal for ImmunoTherapy of Cancer CrossRef - HER3 in cancer: from the bench to the bedside
Lucía Gandullo-Sánchez et al, 2022, Journal of Experimental & Clinical Cancer Research CrossRef